Biomm

Biomm Gross Margin

The Gross Margin of Biomm (BIOM3.SA) as of Nov 11, 2026 is 30.36 %. In the previous year, Gross Margin was 12.51 % — a change of 142.64% (higher).

Gross Margin

30.36 %

YoY

142.64%

Last updated:

Gross Margin of Biomm is 2025 30.36 % . Gross Margin of Biomm was 2024 12.51 % . It decreases by 142.64% higher compared to the previous year.

Biomm's gross margin stands at 30.4%, up from 25.2% several years earlier.

The Biomm Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
15.64 BRL
Jan 1, 2019
5.83 BRL
Jan 1, 2020
23.75 BRL
Jan 1, 2021
25.15 BRL
Jan 1, 2022
15.24 BRL
Jan 1, 2023
19.68 BRL
Jan 1, 2024
12.51 BRL
Jan 1, 2025
30.36 BRL
The Biomm Gross Margin history
YEARGross MarginYoY
30.36 %+142.64%
12.51 %-36.41%
19.68 %+29.12%
15.24 %-39.40%
25.15 %+5.88%
23.75 %+307.78%
5.83 %-62.77%
15.64 %-55.24%
34.95 %+6,850.66%
0.50 %-21.61%
0.64 %+108.54%
0.31 %+31.97%
0.23 %-64.39%
0.65 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biomm Stock analysis

What does Biomm do? Biomm SA generates revenue through the development and licensing of technology for producing human insulin and other recombinant proteins. The company's patented technology, protected in multiple regions, is used by pharmaceutical firms to manufacture therapeutic proteins for drugs and biopharmaceuticals. Its subsidiaries Biomm International Inc, Biomm Middle East Inc, and Biomm Russia Ltd support global operations. The firm also develops production processes for enzymes used in biomass hydrolysis and bio-fuel manufacturing, targeting industrial applications in renewable energy sectors. The primary buyers of Biomm SA's technology are pharmaceutical companies seeking to produce therapeutic proteins. These firms license the company's patented insulin production methods to integrate into their drug manufacturing processes. The enzyme production technology is sold to companies in the bio-fuel industry, particularly those involved in biomass conversion for renewable energy. Biomm SA's focus on recombinant protein production and bio-fuel applications positions it within the biotechnology and renewable energy markets. The company's business model relies on technology licensing fees and sales of proprietary production processes. Insulin production technology, protected by international patents, forms a significant revenue stream. Enzyme technology for biomass hydrolysis and bio-fuel manufacturing provides additional income from industrial clients. Biomm SA's subsidiaries facilitate international market access, enabling the company to serve global clients across pharmaceutical and renewable energy sectors. Biomm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biomm stock

Gross Margin of Biomm is 30.36 % in 2025.

Gross Margin of Biomm changed from 12.51 % to 30.36 %, representing a 142.64% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Biomm since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Biomm with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Biomm

All Key Metrics — Biomm